BioSpace News Archive

ATI Physical Therapy, one of the nation’s largest providers of physical therapy services, announced the hiring of John Sanford as Vice President of Design, Construction and Facilities.

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) (“BioVaxys” or “Company”) is pleased to announce that it has initiated the clinical development program for Covid-T™, the Company’s novel diagnostic platform for detecting T-cell activity

Artiva Biotherapeutics, Inc., an oncology company focused on developing and commercializing primary allogeneic natural killer (NK) cell therapies to treat cancer, announced today that it has entered into an exclusive worldwide collaboration and license agreement with Merck, known as MSD outside the United States and Canada, to develop novel chimeric antigen receptor (CAR)-NK cell therapies targeting solid tumor-associated antigens.

Charles River Announces Strategic Partnership with Cypre, Expanding 3D In Vitro Services for Cancer Immunotherapy and Targeted Therapy Drug Screening

Ancora Heart, Inc., a company developing a novel therapy to address heart failure, today announced enrollment of the first patient in the CORCINCH-HF pivotal trial, which is designed to evaluate the safety and efficacy of the AccuCinch® Ventricular Restoration System in patients who have symptomatic heart failure (HF) with reduced ejection fraction (HFrEF).

24/7 cloud-based wireless monitoring ensures vaccines are stored throughout the cold chain in the required sub-zero temperature ranges down to -100°C.

HD Medical Inc. announces additions to its executive team and advisory board to support the company’s accelerated growth.

Scitara Corporation, a global provider of laboratory-specific, cloud-based software solutions for the biopharmaceutical and industrial markets, today announced the closing of $5 million in a Series A round.

Bioceres Crop Solutions Corp. (“Bioceres”) (NYSE American: BIOX), a fully-integrated provider of crop productivity solutions designed to enable the transition of agriculture towards carbon neutrality, will hold a conference call on Thursday, February 11, 2021 at 8:30 a.m. Eastern time to discuss its results for the fiscal second quarter ended December 31, 2020.

Novaremed AG (Novaremed), a clinical-stage Swiss biopharmaceutical company, announced today that it has signed an agreement with GEM Global Yield LLC SCS (GEM), a Luxembourg-based private, alternative investment group for a US $50 million capital commitment.